SHANGHAI SERUM BIO-TECHNOLOGY released its performance for the first three quarters, with a net profit attributable to the parent company of 64.21 million yuan, a year-on-year increase of 2.01%
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, SHANGHAI SERUM BIO-TECHNOLOGY disclosed its third-quarter report for 2025. The company achieved revenue of 175 million yuan in the first three quarters, a year-on-year increase of 1.07%; net profit attributable to shareholders was 64.21 million yuan, a year-on-year increase of 2.01%; net profit excluding non-recurring items was 56.44 million yuan, a year-on-year increase of 12.15%; basic earnings per share were 0.59 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments